Copyright
©The Author(s) 2017.
World J Clin Infect Dis. May 25, 2017; 7(2): 21-31
Published online May 25, 2017. doi: 10.5495/wjcid.v7.i2.21
Published online May 25, 2017. doi: 10.5495/wjcid.v7.i2.21
Table 3 Minimum inhibitory concentrations for clinical isolates of Entamoeba histolytica to metronidazole and auranofin in drug susceptibity assays
| Isolate | MIC metronidazole | Range (µmol/L) | MIC auranofin | Range (µmol/L) | No. of attempts |
| 654 | 50 μmol/L | 50-60 | 2 μmol/L | 2-3 | 3 |
| 812 | 40 μmol/L | 30-40 | 2 μmol/L | 2-3 | 3 |
| 980 | 80 μmol/L | 80-100 | 3 μmol/L | 80-100 | 5 (auranofin) |
| 10 (metronidazole) | |||||
| 989 | 30 μmol/L | 30-40 | 1 μmol/L | 1-2 | 5 |
| 5132 | 50 μmol/L | 50-60 | 2 μmol/L | 2-3 | 3 |
| MS-96:3382 | 24 μmol/L | 20-30 | 5 μmol/L | 4-5 | 4 |
- Citation: Iyer LR, Banyal N, Naik S, Paul J. Antioxidant enzyme profile of two clinical isolates of Entamoeba histolytica varying in sensitivity to antiamoebic drugs. World J Clin Infect Dis 2017; 7(2): 21-31
- URL: https://www.wjgnet.com/2220-3176/full/v7/i2/21.htm
- DOI: https://dx.doi.org/10.5495/wjcid.v7.i2.21